
APUS
Apimeds Pharmaceuticals US Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.400
Open
2.130
VWAP
2.20
Vol
152.34K
Mkt Cap
25.70M
Low
2.100
Amount
335.35K
EV/EBITDA(TTM)
--
Total Shares
11.58M
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Show More
Valuation Metrics
The current forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Apimeds Pharmaceuticals US Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+34.09%
-364.37K
Operating Profit
FY2025Q1
YoY :
+35.73%
-402.40K
Net Income after Tax
FY2025Q1
YoY :
+66.67%
-0.05
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
APUS News & Events
News
5.0
07-15NewsfilterApimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
Sign Up For More News
People Also Watch

MSFT
Microsoft Corp
513.710
USD
+0.55%

AMZN
Amazon.com Inc
231.440
USD
-0.34%

NVDA
NVIDIA Corp
173.500
USD
-0.14%

AAPL
Apple Inc
213.880
USD
+0.06%

AVGO
Broadcom Inc
290.180
USD
+0.51%

TSLA
Tesla Inc
316.060
USD
+3.52%

META
Meta Platforms Inc
712.680
USD
-0.30%

ORCL
Oracle Corp
245.120
USD
+0.94%

XOM
Exxon Mobil Corp
110.400
USD
-0.35%

WMT
Walmart Inc
97.470
USD
+0.90%
FAQ

What is Apimeds Pharmaceuticals US Inc (APUS) stock price today?
The current price of APUS is 2.22 USD — it has increased 6.22 % in the last trading day.

What is Apimeds Pharmaceuticals US Inc (APUS)'s business?

What is the price predicton of APUS Stock?

What is Apimeds Pharmaceuticals US Inc (APUS)'s revenue for the last quarter?

What is Apimeds Pharmaceuticals US Inc (APUS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Apimeds Pharmaceuticals US Inc (APUS)'s fundamentals?

How many employees does Apimeds Pharmaceuticals US Inc (APUS). have?
